Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.

Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM.

Hepatol Int. 2011 Dec;5(4):927-33. doi: 10.1007/s12072-011-9266-y. Epub 2011 Mar 12.

PMID:
21484118
2.

Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels.

Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH.

Liver Int. 2009 Nov;29(10):1521-7. doi: 10.1111/j.1478-3231.2009.02105.x. Epub 2009 Sep 2.

PMID:
19725889
3.

Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels.

Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, An H, Kim JH, Seo YS, Kim YS, Yim HJ, Jeen YT, Lee HS, Um SH, Kim CD, Ryu HS.

Korean J Hepatol. 2011 Jun;17(2):130-8. doi: 10.3350/kjhep.2011.17.2.130.

4.

Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites.

Seo YS, Park SY, Kim MY, Kim SG, Park JY, Yim HJ, Jang BK, Park SH, Kim JH, Suk KT, Kim JD, Kim TY, Cho EY, Lee JS, Jung SW, Jang JY, An H, Tak WY, Baik SK, Hwang JS, Kim YS, Sohn JH, Um SH.

J Gastroenterol Hepatol. 2018 Apr;33(4):910-917. doi: 10.1111/jgh.13983. Epub 2018 Jan 26.

PMID:
28910501
5.

Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.

Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, Moreau R, Teupser D, Wendon J, Nevens F, Trebicka J, Garcia E, Pavesi M, Arroyo V, Gerbes AL.

Hepatology. 2017 Oct;66(4):1232-1241. doi: 10.1002/hep.29290. Epub 2017 Aug 26.

PMID:
28545169
6.

Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels.

Ahn HS, Kim YS, Kim SG, Kim HK, Min SK, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS, Park JM.

Hepatogastroenterology. 2012 Jun;59(116):1168-73. doi: 10.5754/hge11616.

PMID:
22057374
7.

Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome.

Barakat M, Khalil M.

Arab J Gastroenterol. 2011 Sep;12(3):131-5. doi: 10.1016/j.ajg.2011.07.006. Epub 2011 Aug 30.

PMID:
22055590
8.

Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, Li C, Chen J, Xin SJ.

World J Gastroenterol. 2013 Dec 28;19(48):9432-8. doi: 10.3748/wjg.v19.i48.9432.

9.

Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis.

Adachi M, Tanaka A, Aiso M, Takamori Y, Takikawa H.

Hepatol Res. 2015 Dec;45(13):1299-306. doi: 10.1111/hepr.12508. Epub 2015 Apr 10.

PMID:
25704216
10.

Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome.

Demirtaş S, Bozbaş A, Akbay A, Yavuz Y, Karaca L.

Clin Chim Acta. 2001 Sep 25;311(2):81-9.

PMID:
11566167
11.

Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis.

Xirouchakis E, Marelli L, Cholongitas E, Manousou P, Calvaruso V, Pleguezuelo M, Guerrini GP, Maimone S, Kerry A, Hajjawi M, Nair D, Thomas M, Patch D, Burroughs AK.

Clin J Am Soc Nephrol. 2011 Jan;6(1):84-92. doi: 10.2215/CJN.03400410. Epub 2010 Sep 9.

12.

Predictors of hepatorenal syndrome in alcoholic liver cirrhosis.

Janicko M, Veseliny E, Senajova G, Jarcuska P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):661-5. doi: 10.5507/bp.2015.010. Epub 2015 Mar 26.

13.

New Developments in Hepatorenal Syndrome.

Mindikoglu AL, Pappas SC.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Epub 2017 Jun 7.

PMID:
28602971
14.

Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus.

Bodnar L, Stec R, Dzierżanowska M, Synowiec A, Cierniak S, Kade G, Szczylik C.

Cancer Chemother Pharmacol. 2016 Aug;78(2):295-304. doi: 10.1007/s00280-016-3084-9. Epub 2016 Jun 20.

PMID:
27324020
15.

Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index.

Vupputuri S, Fox CS, Coresh J, Woodward M, Muntner P.

Am J Kidney Dis. 2009 Jun;53(6):993-1001. doi: 10.1053/j.ajkd.2008.12.043. Epub 2009 Apr 25.

16.

Comparison of creatinine and cystatin formulae with 51 Chromium-ethylenediaminetetraacetic acid glomerular filtration rate in patients with decompensated cirrhosis.

Cholongitas E, Ioannidou M, Goulis I, Chalevas P, Ntogramatzi F, Athanasiadou Z, Notopoulos A, Alevroudis M, Sinakos E, Akriviadis E.

J Gastroenterol Hepatol. 2017 Jan;32(1):191-198. doi: 10.1111/jgh.13446.

PMID:
27177318
17.

Estimating the glomerular filtration rate using serum cystatin C levels in patients with spinal cord injuries.

Erlandsen EJ, Hansen RM, Randers E, Petersen LE, Abrahamsen J, Johannesen IL.

Spinal Cord. 2012 Oct;50(10):778-83. doi: 10.1038/sc.2012.52. Epub 2012 May 1.

PMID:
22547045
18.

Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis.

Shin MJ, Song SH, Kwak IS, Lee SB, Lee DW, Seong EY, Kim IY, Rhee H, Lee N.

Clin Exp Nephrol. 2012 Jun;16(3):456-63. doi: 10.1007/s10157-011-0583-1. Epub 2012 Jan 26.

PMID:
22278599
19.

Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis.

Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, Chan TM.

Dig Liver Dis. 2017 Feb;49(2):202-206. doi: 10.1016/j.dld.2016.11.001. Epub 2016 Nov 10.

PMID:
27876501
20.

Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis.

Sato H, Kuroda T, Tanabe N, Ajiro J, Wada Y, Murakami S, Sakatsume M, Nakano M, Gejyo F.

Scand J Rheumatol. 2010;39(1):33-7. doi: 10.3109/03009740903042402.

PMID:
20132068

Supplemental Content

Support Center